New hope for Tough-to-Treat ovarian cancer
NCT ID NCT04089189
Summary
This study tested a new oral medication called IMP4297 for women with advanced ovarian cancer that has a specific genetic change (BRCA mutation) and has stopped responding to at least two standard treatments. The main goal was to see if the drug could shrink tumors and control the cancer, while also checking its safety. The trial involved 93 participants in China and did not compare the drug to another treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Xiaohua.Wu
Shanghai, China
Conditions
Explore the condition pages connected to this study.